LXEO · ISSUER CIK 1907108
Lexeo Therapeutics, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Lexeo Therapeutics, Inc. insiders reported $0.00 of open-market purchases and $43K of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 3 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$43KInsider selling
−$43KNet open-market
Sep 28, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 202617:15 | Sep 14, 2026 | LXEO | Chief Medical Officer | A · GrantLate 14d | $3.58 | +2,714 | 84,908 | +3% | $10K | ||
| Sep 28, 202617:15 | Sep 14, 2026 | LXEO | Chief Operating Officer | A · GrantLate 14d | $2.64 | +2,110 | 138,288 | +2% | $6K | ||
| Sep 28, 202617:15 | Sep 14, 2026 | LXEO | Chief Executive Officer, Director | A · GrantLate 14d | $2.64 | +2,306 | 376,778 | +1% | $6K | ||
| Aug 19, 202617:00 | Aug 18, 2026 | LXEO | Chief Financial Officer | S · Sell | $4.91 | −4,117 | 92,907 | -4% | −$20K | ||
| Aug 19, 202617:00 | Aug 18, 2026 | LXEO | Chief Executive Officer, Director | S · Sell | $4.95 | −3,345 | 374,472 | -1% | −$17K | ||
| Aug 19, 202617:00 | Aug 18, 2026 | LXEO | Chief Operating Officer | S · Sell | $4.96 | −1,304 | 136,178 | -1% | −$6K |